Research ExplorerPublicationsPrognostic Value of a Novel and Established High-Sensitivity...

Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction

Standard

Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction. / Sörensen, Nils A; Ludwig, Sebastian; Makarova, Nataliya; Neumann, Johannes T; Lehmacher, Jonas; Hartikainen, Tau S; Haller, Paul M; Keller, Till; Blankenberg, Stefan; Westermann, Dirk; Zeller, Tanja; Schofer, Niklas.

In: BIOMOLECULES, Vol. 9, No. 9, 09.09.2019.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sörensen, NA, Ludwig, S, Makarova, N, Neumann, JT, Lehmacher, J, Hartikainen, TS, Haller, PM, Keller, T, Blankenberg, S, Westermann, D, Zeller, T & Schofer, N 2019, 'Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction', BIOMOLECULES, vol. 9, no. 9. https://doi.org/10.3390/biom9090469

APA

Sörensen, N. A., Ludwig, S., Makarova, N., Neumann, J. T., Lehmacher, J., Hartikainen, T. S., Haller, P. M., Keller, T., Blankenberg, S., Westermann, D., Zeller, T., & Schofer, N. (2019). Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction. BIOMOLECULES, 9(9). https://doi.org/10.3390/biom9090469

Vancouver

Sörensen NA, Ludwig S, Makarova N, Neumann JT, Lehmacher J, Hartikainen TS et al. Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction. BIOMOLECULES. 2019 Sep 9;9(9). https://doi.org/10.3390/biom9090469

Bibtex

@article{b1f7a65a463849c7b95256732af75331,
title = "Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction",
abstract = ": High-sensitivity troponin has proven to be a promising biomarker for the prediction of future adverse cardiovascular events. We aimed to assess the prognostic value of high-sensitivity troponin I (hs-TnI) on admission in patients with suspected acute myocardial infarction (AMI) analyzed by a novel (Singulex Clarity cTnI) and established hs-TnI assay (ARCHITECT STAT hs-TnI, Abbott). Hs-TnI was measured in a total of 2332 patients from two prospective cohort studies presenting to the emergency department with suspected AMI. The prognostic impact for overall and cardiovascular mortality of both hs-TnI assays was assessed in the total patient cohort as well as in the subgroups of patients with AMI (n = 518) and without AMI (non-AMI) (n = 1814). Patients presenting with highest hs-TnI levels showed higher overall and cardiovascular mortality rates compared to those with lower troponin levels, irrespective of the assay used. Both hs-TnI assays indicated association with overall mortality according to adjusted hazard ratio (HR) among the entire study population (HR for Singulex assay: 1.16 (95% CI 1.08-1.24) and HR for Abbott assay: 1.17 (95% CI 1.09-1.25)). This finding was particularly pronounced in non-AMI patients, whereas no association between hs-TnI and overall mortality was found in AMI patients for either assay. In non-AMI patients, both assays equally improved risk prediction for cardiovascular mortality beyond conventional cardiovascular risk factors. Hs-TnI is independently predictive for adverse outcomes in patients with suspected AMI, especially in the subset of patients without confirmed AMI. There was no difference between the established and the novel assay in the prediction of mortality.",
keywords = "Aged, Female, Humans, Limit of Detection, Male, Middle Aged, Myocardial Infarction/diagnosis, Patient Admission, Prognosis, Risk Assessment, Survival Analysis, Troponin I/metabolism",
author = "S{\"o}rensen, {Nils A} and Sebastian Ludwig and Nataliya Makarova and Neumann, {Johannes T} and Jonas Lehmacher and Hartikainen, {Tau S} and Haller, {Paul M} and Till Keller and Stefan Blankenberg and Dirk Westermann and Tanja Zeller and Niklas Schofer",
year = "2019",
month = sep,
day = "9",
doi = "10.3390/biom9090469",
language = "English",
volume = "9",
journal = "BIOMOLECULES",
issn = "2218-273X",
publisher = "Multidisciplinary Digital Publishing Institute",
number = "9",

}

RIS

TY - JOUR

T1 - Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction

AU - Sörensen, Nils A

AU - Ludwig, Sebastian

AU - Makarova, Nataliya

AU - Neumann, Johannes T

AU - Lehmacher, Jonas

AU - Hartikainen, Tau S

AU - Haller, Paul M

AU - Keller, Till

AU - Blankenberg, Stefan

AU - Westermann, Dirk

AU - Zeller, Tanja

AU - Schofer, Niklas

PY - 2019/9/9

Y1 - 2019/9/9

N2 - : High-sensitivity troponin has proven to be a promising biomarker for the prediction of future adverse cardiovascular events. We aimed to assess the prognostic value of high-sensitivity troponin I (hs-TnI) on admission in patients with suspected acute myocardial infarction (AMI) analyzed by a novel (Singulex Clarity cTnI) and established hs-TnI assay (ARCHITECT STAT hs-TnI, Abbott). Hs-TnI was measured in a total of 2332 patients from two prospective cohort studies presenting to the emergency department with suspected AMI. The prognostic impact for overall and cardiovascular mortality of both hs-TnI assays was assessed in the total patient cohort as well as in the subgroups of patients with AMI (n = 518) and without AMI (non-AMI) (n = 1814). Patients presenting with highest hs-TnI levels showed higher overall and cardiovascular mortality rates compared to those with lower troponin levels, irrespective of the assay used. Both hs-TnI assays indicated association with overall mortality according to adjusted hazard ratio (HR) among the entire study population (HR for Singulex assay: 1.16 (95% CI 1.08-1.24) and HR for Abbott assay: 1.17 (95% CI 1.09-1.25)). This finding was particularly pronounced in non-AMI patients, whereas no association between hs-TnI and overall mortality was found in AMI patients for either assay. In non-AMI patients, both assays equally improved risk prediction for cardiovascular mortality beyond conventional cardiovascular risk factors. Hs-TnI is independently predictive for adverse outcomes in patients with suspected AMI, especially in the subset of patients without confirmed AMI. There was no difference between the established and the novel assay in the prediction of mortality.

AB - : High-sensitivity troponin has proven to be a promising biomarker for the prediction of future adverse cardiovascular events. We aimed to assess the prognostic value of high-sensitivity troponin I (hs-TnI) on admission in patients with suspected acute myocardial infarction (AMI) analyzed by a novel (Singulex Clarity cTnI) and established hs-TnI assay (ARCHITECT STAT hs-TnI, Abbott). Hs-TnI was measured in a total of 2332 patients from two prospective cohort studies presenting to the emergency department with suspected AMI. The prognostic impact for overall and cardiovascular mortality of both hs-TnI assays was assessed in the total patient cohort as well as in the subgroups of patients with AMI (n = 518) and without AMI (non-AMI) (n = 1814). Patients presenting with highest hs-TnI levels showed higher overall and cardiovascular mortality rates compared to those with lower troponin levels, irrespective of the assay used. Both hs-TnI assays indicated association with overall mortality according to adjusted hazard ratio (HR) among the entire study population (HR for Singulex assay: 1.16 (95% CI 1.08-1.24) and HR for Abbott assay: 1.17 (95% CI 1.09-1.25)). This finding was particularly pronounced in non-AMI patients, whereas no association between hs-TnI and overall mortality was found in AMI patients for either assay. In non-AMI patients, both assays equally improved risk prediction for cardiovascular mortality beyond conventional cardiovascular risk factors. Hs-TnI is independently predictive for adverse outcomes in patients with suspected AMI, especially in the subset of patients without confirmed AMI. There was no difference between the established and the novel assay in the prediction of mortality.

KW - Aged

KW - Female

KW - Humans

KW - Limit of Detection

KW - Male

KW - Middle Aged

KW - Myocardial Infarction/diagnosis

KW - Patient Admission

KW - Prognosis

KW - Risk Assessment

KW - Survival Analysis

KW - Troponin I/metabolism

U2 - 10.3390/biom9090469

DO - 10.3390/biom9090469

M3 - SCORING: Journal article

C2 - 31505902

VL - 9

JO - BIOMOLECULES

JF - BIOMOLECULES

SN - 2218-273X

IS - 9

ER -